Curated News
By: NewsRamp Editorial Staff
September 03, 2026
OS Therapies to Present at Moody Capital Conference Amid Key Regulatory Milestones for OST-HER2
TLDR
- OS Therapies' OST-HER2 could secure regulatory advantages and market position in osteosarcoma treatment by Q4 2026.
- OS Therapies' OST-HER2 uses listeria-based immunotherapy targeting HER2 epitopes, with FDA and EMA designations, and key data expected in September.
- OS Therapies' OST-HER2 aims to improve survival for osteosarcoma patients, with potential approvals expanding treatment options.
- OS Therapies presents at Moody Capital 2026, with OS Animal Health seeking USDA approval for canine osteosarcoma.
Impact - Why it Matters
This news is significant for investors and patients alike. OS Therapies is approaching critical regulatory decisions and data readouts for OST-HER2, a potential breakthrough therapy for osteosarcoma, a rare bone cancer with limited treatment options. The upcoming interim survival data and FDA/UK meetings could determine the therapy's path to approval, impacting future treatment paradigms. For investors, these milestones represent potential catalysts that could affect the company's valuation. Additionally, the company's efforts to expand into veterinary oncology for canine osteosarcoma broaden its market potential. Understanding these developments is crucial for stakeholders tracking advancements in oncology and rare disease treatments.
Summary
OS Therapies (NYSE American: OSTX), a clinical-stage oncology company, is set to present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City from September 9-10, where its subsidiary OS Animal Health will also participate. The company will engage with investors and strategic partners during this pivotal time. OS Therapies is anticipating a critical regulatory period for OST-HER2, its investigational immunotherapy for fully resected pulmonary metastatic osteosarcoma. Expected milestones include interim three-year overall survival data and key FDA and U.K. regulatory meetings in September, followed by potential RMAT and Rolling Review decisions. The company targets final three-year data, a U.S. Pre-BLA meeting, and regulatory submissions in the U.S., U.K., and Europe for Q4 2026. Meanwhile, OS Animal Health is seeking USDA alignment on reinstating conditional approval for OST-HER2 in canine osteosarcoma.
OST-HER2 leverages the immune-stimulatory effects of listeria bacteria to target the HER2 protein, which is present in various solid tumors. It is designed to trigger an immune response by recognizing three epitopes of the HER2 oncogene, requiring only one to be present. The therapy has received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation from the U.S. FDA, as well as Advanced Therapy Medicinal Products designation from the European Medicines Agency. OS Therapies is committed to developing treatments for osteosarcoma and other solid tumors, positioning itself as a leader in gene-edited, listeria-based cancer immunotherapies. For more details, visit the full press release at https://ibn.fm/ERaOp and the company's website at www.ostherapies.com.
The conference is hosted by InvestorWire, a specialized communications platform that provides press release syndication and corporate communications solutions. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions and editorial syndication to 5,000+ outlets. This participation highlights OS Therapies' proactive engagement with the investment community as it advances its pipeline.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, OS Therapies to Present at Moody Capital Conference Amid Key Regulatory Milestones for OST-HER2
